UltraSPECT, dose management, lower dose SPECT
GE, CZT, Discovery NM 570c

Nuclear myocardial perfusion imaging (MPI) with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) have been the gold standard for noninvasive detection of coronary ischemia and infarcts. However, the high radiation doses patients receive are making some providers think twice before referring their patients for nuclear MPI. 

Contego Medical announced the completion of a $5.6 million Series B financing round, led by Hatteras Venture Partners. Hatteras is an early stage venture firm with a focus on medical devices, biopharmaceuticals, diagnostics and related opportunities in human medicine. The round also included Mountain Group Partners, Lookout Capital and Medical Mutual.

Penn Medicine’s Penn Care at Home program reported a 53 percent reduction in 30-day readmission rates for 130 congestive heart failure patients since implementing software from Health Recovery Solutions. Readmission rates dropped from 8 percent to 3.8 percent over a period from July 2014 to February 2015.


The Healthcare Information and Management Systems Society (HIMSS) released the results of the 2015 HIMSS Mobile Technology Survey. This year’s study, of more than 200 healthcare provider employees, found that nearly 90 percent of respondents are utilizing mobile devices within their organizations to engage patients in their healthcare. The report also showed that respondents believe that mobile health (mHealth) technologies are beginning to drive cost savings and improve the quality of care delivered.
 

On April 17, 2015 the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule to update fiscal year (FY) 2016 Medicare payment policies and rates under the Inpatient Prospective Payment System (IPPS) and the Long-Term Care Hospital (LTCH) Prospective Payment System (PPS). The proposed rule, which would apply to approximately 3,400 acute care hospitals and approximately 435 LTCHs, would affect discharges occurring on or after Oct. 1, 2015.

EBR Systems Inc. announced it has raised $20 million for clinical studies and regulatory filings, including commitments toward a second quarter closing. EBR Systems is using the funds to build on promising European clinical work; obtain CE Mark for the company’s proprietary wireless pacing system; obtain approval for a U.S. Investigational Device Exemption (IDE) clinical study; and complete development of its second generation system that is smaller and more energy efficient.


The latest advances in echocardiography were discussed at a special evening symposium at the 2015 American College of Cardiology (ACC) meeting, organized by Methodist Debakey Heart and Vascular Center. 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now